• 1
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 3749.
  • 2
    Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther 1997; 19: (Suppl. A): 3952.
  • 3
    Greenland P, Daviglus ML, Dyer AR, Liu K, Huang C, Goldberger JJ, Stamler J. Resting Heart Rate is a risk factor for cardiovascular and noncardiovascular mortality. Am J Epidemiol 1999; 149: 85362.
  • 4
    Singh B. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5: (Suppl. G): G3G9.
  • 5
    Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004; 26: 63744.
  • 6
    Lanza GA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol 2006; 43: 116.
  • 7
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 81721.
  • 8
    Hsia J, Larson JC, Ockene JK, Sarto GE, Allison MA, Hendrix SL, Robinson JG, LaCroix AZ, Manson JE. Women's Health Initiative Research Group. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009; 338: b219.
  • 9
    Tjugen TB, Flaa A, Kjeldsen SE. The prognostic significance of heart rate for cardiovascular disease and hypertension. Curr Hypertens Rep 2010; 12: 1629.
  • 10
    Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010; 106: 26874.
  • 11
    Wang PS, Levin R, Zhao SZ, Avorn J. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. J Am Geriatr Soc 2002; 50: 11724.
  • 12
    Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 101322.
  • 13
    Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992; 42: 57780.
  • 14
    Dmochowski R, Staskin DR. The Q-T interval and antimuscarinic drugs. Curr Urol Rep 2005; 6: 4059.
  • 15
    Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 4639.
  • 16
    Ardell JL, Randall WC. Selective vagal innervation of sinoatrial and atrioventricular nodes in canine heart. Am J Physiol 1986; 251: H76473.
  • 17
    Loffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart. Pharmacol Rev 1985; 37: 124.
  • 18
    Randall WC, Milosavljevic M, Wurster RD, Geis GS, Ardell JL. Selective vagal innervation of the heart. Ann Clin Lab Sci 1986; 16: 198208.
  • 19
    Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res 1971; 29: 43745.
  • 20
    Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007; 74: 22442.
  • 21
    Chapleau MW, Sabharwal R. Methods of assessing vagus nerve activity and reflexes. Heart Fail Rev 2010; DOI: 10.1007/s10741-010-9174-6 [Epub ahead of print].
  • 22
    Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007; 100: 100714.
  • 23
    Gopinathannair R, Sullivan RM, Olshansky B. Slower heart rates for healthy hearts: time to redefine tachycardia? Circ Arrythm Electrophysiol 2008; 1: 3213.
  • 24
    Goldberger JJ, Le FK, Lahiri M, Kannankeril PJ, Ng J, Kadish AH. Assessment of parasympathetic reactivation after exercise. Am J Physiol Heart Circ Physiol 2006; 290: H244652.
  • 25
    Falcone C, Buzzi MP, Klersy C, Schwartz PJ. Rapid heart rate increase at onset of exercise predicts adverse cardiac events in patients with coronary artery disease. Circulation 2005; 112: 195964.
  • 26
    Leeper NJ, Dewey FE, Ashley EA, Sandri M, Tan SY, Hadley D, Myers J, Froelicher V. Prognostic value of heart rate increase at onset of exercise testing. Circulation 2007; 115: 46874.
  • 27
    Chaitman BR. Should early acceleration of heart rate during exercise be used to risk stratify patients with suspected or established coronary artery disease? Circulation 2007; 115: 4301.
  • 28
    Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 19518.
  • 29
    Elghozi JL, Girard A, Laude D. Effects of drugs on the autonomic control of short term heart rate variability. Auton Neurosci 2001; 90: 11621.
  • 30
    Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10: 88101.
  • 31
    Scheinin H, Helminen A, Huhtala S, Gronroos P, Bosch JA, Kuusela T, Kanto J, Kaila T. Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect – integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. Ther Drug Monit 1999; 21: 14151.
  • 32
    Penttila J, Vesalainen R, Helminen A, Kuusela T, Hinkka S, Rahi K, Kaila T, Scheinin H. Spontaneous baroreflex sensitivity as a dynamic measure of cardiac anticholinergic drug effect. J Auton Pharmacol 2001; 21: 718.
  • 33
    Penttila J, Kuusela T, Scheinin H. Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans. Eur J Clin Pharmacol 2005; 61: 55965.
  • 34
    Schiffers M, Sauermann P, Schurch B, Mehnert U. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 2010; 28: 6516.
  • 35
    La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 47884.
  • 36
    La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr, Camm AJ, Schwartz PJ, ATRAMI Investigators. Autonomic Tone and Reflexes After Myocardial Infarction. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001; 103: 20727.
  • 37
    Johansson M, Gao SA, Friberg P, Annerstedt M, Carlström J, Ivarsson T, Jensen G, Ljungman S, Mathillas O, Nielsen FD, Strömbom U. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens 2007; 25: 1638.
  • 38
    Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001; 44: 16182.
  • 39
    Wang Z, Shi H, Wang H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 2004; 142: 395408.
  • 40
    Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006; 100: 32337.
  • 41
    Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton Autacoid Pharmacol 2007; 27: 111.
  • 42
    Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, Grinberg A, Sheng H, Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 16927.
  • 43
    Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000; 292: 87785.
  • 44
    Stengel PW, Yamada M, Wess J, Cohen ML. M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 2002; 282: R14439.
  • 45
    Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M. M1–M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 2003; 9: 27990.
  • 46
    Islam MA, Nojima H, Kimura I. Muscarinic M1 receptor activation reduces maximum upstroke velocity of action potential in mouse right atria. Eur J Pharmacol 1998; 346: 22736.
  • 47
    Colecraft HM, Egamino JP, Sharma VK, Sheu SS. Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. J Biol Chem 1998; 273: 3215866.
  • 48
    Dobrev DK, Richter F, Wettwer E, Christ T, Knaut M, Ravens U. Functional identification of M1 and M3 muscarinic acetylcholine receptors in human atrial myocytes: influence of chronic atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2003; 267: (Suppl. 1): R94.
  • 49
    Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, Nathanson NM. Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. J Pharmacol Exp Ther 2002; 301: 12937.
  • 50
    Poller U, Nedelka G, Radke J, Pönicke K, Brodde OE. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol 1997; 29: 18793.
  • 51
    Brodde OE, Konschak U, Becker K, Rüter F, Poller U, Jakubetz J, Radke J, Zerkowski HR. Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. J Clin Invest 1998; 101: 4718.
  • 52
    Dhein S, Röhnert P, Markau S, Kotchi-Kotchi E, Becker K, Poller U, Osten B, Brodde OE. Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 2000; 36: 60817.
  • 53
    Schäfers RF, Poller U, Pönicke K, Geissler M, Daul AE, Michel MC, Brodde OE. Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 23949.
  • 54
    Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci 2000; 66: 60715.
  • 55
    Ponicke K, Heinroth-Hoffmann I, Brodde OE. Demonstration of functional M3-muscarinic receptors in ventricular cardiomyocytes of adult rats. Br J Pharmacol 2003; 138: 15660.
  • 56
    Willmy-Matthes P, Leineweber K, Wangemann T, Silber RE, Brodde OE. Existence of functional M3-muscarinic receptors in the human heart. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 3169.
  • 57
    Niihashi M, Esumi M, Kusumi Y, Sato Y, Sakurai I. Expression of muscarinic receptor genes in the human coronary artery. Angiology 2000; 51: 295300.
  • 58
    Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis 2004; 46: 34973.
  • 59
    Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986; 74: 95563.
  • 60
    Choi SS, Lim YJ, Bahk JH, Do SH, Ham BM. Coronary artery spasm induced by carotid sinus stimulation during neck surgery. Br J Anaesth 2003; 90: 3914.
  • 61
    Lamping KG, Wess J, Cui Y, Nuno DW, Faraci FM. Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004; 24: 12538.
  • 62
    van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010; 70: 1623.
  • 63
    Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006; 147: S807.
  • 64
    Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 124385.
  • 65
    Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 65190.
  • 66
    Alabaster VA. Discovery and development of selective M3 antagonists for clinical use. Life Sci 1997; 60: 105360.
  • 67
    McCafferty GP, Coatney RW, Laping NJ, Thorneloe KS. Urodynamic measurements by radiotelemetry in conscious, freely moving beagle dogs. J Urol 2009; 181: 144451.
  • 68
    Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants >or =50 years. J Cardiovasc Pharmacol Ther 2008; 13: 24151.
  • 69
    Olshansky B, Spierings ELH, Brum J, Mongay L, Egermark M, Seifu Y. Validation of the differential cardiovascular effects of the antimuscarinic agents darifenacin and tolterodine in a randomized, placebo-controlled, 3-way crossover study. Uro Today Int J 2009; 2: doi:10.3834/uij.1944-5784.2009.08.07.
  • 70
    Novartis. Enablex (Darifenacin) Prescribing Information. January 2010. Available at (last accessed 18 October 2010).
  • 71
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 54362.
  • 72
    Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005; 96: 105562.
  • 73
    Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 178796.
  • 74
    Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of overactive bladder. Ann Pharmacother 2009; 43: 19922000.
  • 75
    Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009; 16: 44819.
  • 76
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 120412.
  • 77
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 248894.
  • 78
    Malhotra B, Wood N, Sachse R, Gandelman K. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010; 48: 30918.
  • 79
    Jones SE, Kasamaki Y, Shuba LM, Ogura T, McCullough JR, McDonald TF. Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 2000; 35: 33440.
  • 80
    Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V. 1032 Study Group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13: 6928.
  • 81
    Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 2005; 48: 1029.
  • 82
    Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996; 41: 735.
  • 83
    Christ T, Wettwer E, Wuest M, Braeter M, Donath F, Champeroux P, Richard S, Ravens U. Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol 2008; 376: 43140.
  • 84
    Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Mürtz G, Frank M, Wieners F. Efficacy and cardiac safety of propiverine in elderly patients – a double-blind, placebo-controlled clinical study. Eur Urol 2000; 37: 7028.
  • 85
    Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31: 50514.
  • 86
    Astellas Pharma US VESIcare® (solifenacin succinate) US prescribing information. July, 2010. Available at (last accessed 10 August 2010).
  • 87
    Asajima H, Sekiguchi Y, Matsushima S, Saito N, Saito T. QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 2008; 66: 8967.
  • 88
    Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, Hendrix J, Rampe D. Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 2004; 308: 93540.
  • 89
    Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol 2006; 48: 199206.
  • 90
    Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007; 81: 37785.
  • 91
    Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 28795.
  • 92
    Pfizer Detrol® (tolterodine tartrate tablets) US prescribing information March, 2008. Available at (last accessed 14 August 2010).
  • 93
    Breuel HP, Mürtz G, Bondy S, Horkulak J, Gianetti BM. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993; 43: 4614.
  • 94
    Guay DR. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 2005; 1: 15767.
  • 95
    Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S. Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 23115.
  • 96
    Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 27580.